Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Be Worth By 2029?
The market size for testing Chlamydia trachomatis (ct) and Neisseria gonorrhoeae (ng) has experienced fast-paced growth in the past few years. The market is set to expand from $1.98 billion in 2024, escalating to $2.19 billion in 2025. This signifies a compound annual growth rate (CAGR) of 10.8%. This substantial growth in the previous years can be credited to factors such as the rise of antibiotic resistance, campaigns promoting awareness and education, as well as changes in policy.
In the following years, the market size of chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing is expected to witness accelerated growth, reaching $3.22 billion in 2029 with an annual growth rate of 10.1% (CAGR). This growth during the projected period is due to factors such as telemedicine and telehealth, advancements in personalized medicine, expansion of point-of-care testing, and strategies related to population health management. The major upcoming trends during this period include spread of rapid point-of-care testing, bespoke testing methods, multi-illness testing platforms, and community-focused testing and outreach programs.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp
What Market Forces Are Contributing To The Growth Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The escalation in sexually transmitted infections (STIs) is anticipated to drive growth in the market for chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing. These infections are diseases brought about by bacteria, viruses, or parasites, which can be transmitted sexually. The rising rates of STIs are attributed to inadequate sex education, increased sexual activity, stigma and various barriers. Testing for Chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) helps in the detection and management of STIs, facilitating early diagnosis, treatment, and prevention of transmission. For example, as per World Health Organization reports published in July 2023, every day, more than 1 million STIs are contracted globally. Additionally, every year, there are approximately 374 million new infections, with one of the four treatable STIs. This increasing incidence of STIs significantly contributes to the expansion of the CTNG testing market.
Which Segments Define The Structure Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testingmarket covered in this report is segmented –
1) By Test Type: Laboratory; Point Of Care Testing
2) By Product: Assays And Kits; Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology; Polymerase Chain Reaction; Immunodiagnostics; Other Technologies
4) By End User: Diagnostic Laboratories; Hospitals And Clinics; Other End Users
Subsegments:
1) By Laboratory: Nucleic Acid Amplification Tests (NAAT); Polymerase Chain Reaction (PCR) Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Immunofluorescence Assay (IFA); Culture Tests; Direct Fluorescent Antibody (DFA) Tests
2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT); Lateral Flow Assays; Immunochromatographic Tests; Self-Testing Kits; Loop-Mediated Isothermal Amplification (LAMP); Microfluidics-Based Tests
Which Long-Term Trends Will Play A Crucial Role In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Leading organizations involved in the testing market for chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) are channeling their efforts towards creating innovative testing solutions such as the BD COR MX/PX System. This high-throughput disease diagnostic platform for infectious diseases is being developed to meet the rising demand for efficient, precise, and scalable testing methodologies that can effectively deal with the growing prevalence of sexually transmitted diseases. The BD COR MX/PX System, a state-of-the-art laboratory tool, has been designed to conduct quick and efficient analysis of a large number of samples for detecting infectious pathogens. For example, in May 2022, Becton Dickinson and Company, a medical device company based in the US, introduced its novel, fully-automated, high-throughput platform for diagnosing infectious diseases, named the BD COR MX/PX System. This system is developed to improve workflow in expansive laboratories that handle numerous infectious disease tests, including assays for chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG). The entire procedure, from receiving samples to generating results, is automated using robots and software algorithms, which could substantially enhance efficiency and possibly reduce the delay in receiving test results. It also includes features like automation, high-throughput capacity, dual DNA targets, and a scalable modular design.
Which Firms Are Making The Biggest Impact In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In The Coming Years?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2024. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=14667&type=smp
Browse Through More Reports Similar to the Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market 2025, By The Business Research Company
Iot Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/iot-testing-global-market-report
Poc Hba1C Testing Market 2025
https://www.thebusinessresearchcompany.com/report/poc-hba1c-testing-market
Veterinary Laboratory Testing Services Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model